Published peptide research references
Semaglutide
Governed registry record
25 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
Open the peptide evidence profile →Approved source records
WEGOVY (semaglutide) prescribing information, revised June 2026
2026
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
W Timothy Garvey, Matthias Blüher, Cynthia Karenina Osorto Contreras, Melanie J Davies, Eva Winning Lehmann, Kirsi H Pietiläinen, Domenica Rubino, Paolo Sbraccia · 2025
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.
Christian S Hendershot, Michael P Bremmer, Michael B Paladino, Georgios Kostantinis, Thomas A Gilmore, Neil R Sullivan, Amanda C Tow, Sarah S Dermody · 2025
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.
Sean Wharton, Paula Freitas, Jøran Hjelmesæth, Maria Kabisch, Kristian Kandler, Ildiko Lingvay, Maria Quiroga, Julio Rosenstock · 2025
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
Darren K McGuire, Nikolaus Marx, Sharon L Mulvagh, John E Deanfield, Silvio E Inzucchi, Rodica Pop-Busui, Johannes F E Mann, Scott S Emerson · 2025
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
2025
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
2024
Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Areesha Moiz, Jeremy Y Levett, Kristian B Filion, Katya Peri, Pauline Reynier, Mark J Eisenberg · 2024
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
Henning Bliddal, Harold Bays, Sébastien Czernichow, Joanna Uddén Hemmingsson, Jøran Hjelmesæth, Thomas Hoffmann Morville, Anna Koroleva, Jesper Skov Neergaard · 2024
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
2023
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
2022
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
2022
Once-Weekly Semaglutide in Adolescents with Obesity
2022
Semaglutide 2.4 mg once a week in adults from east Asia with overweight or obesity, with or without type 2 diabetes (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
2022
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
2022
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
2022
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
2021
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial
2021
Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
2021
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
2021
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
2021
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
2019
The Discovery and Development of Liraglutide and Semaglutide.
2019
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
2016